Davide Melisi

10.3k total citations · 3 hit papers
164 papers, 5.9k citations indexed

About

Davide Melisi is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Davide Melisi has authored 164 papers receiving a total of 5.9k indexed citations (citations by other indexed papers that have themselves been cited), including 125 papers in Oncology, 61 papers in Molecular Biology and 45 papers in Cancer Research. Recurrent topics in Davide Melisi's work include Pancreatic and Hepatic Oncology Research (89 papers), Cancer Genomics and Diagnostics (32 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (30 papers). Davide Melisi is often cited by papers focused on Pancreatic and Hepatic Oncology Research (89 papers), Cancer Genomics and Diagnostics (32 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (30 papers). Davide Melisi collaborates with scholars based in Italy, United States and France. Davide Melisi's co-authors include Giampaolo Tortora, Carmine Carbone, Paul J. Chiao, Fortunato Ciardiello, Geny Piro, Roberto Bianco, Antoine Hollebecque, Hui‐Ling Zhen, Luis Féliz and Camilla Zecchetto and has published in prestigious journals such as The Lancet, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Davide Melisi

157 papers receiving 5.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study

2020 975 citations Antoine Hollebecque, Davide Melisi et al. profile →
Clinicogenomic Analysis of FGFR2 -Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib

2020 191 citations Ian M. Silverman, Antoine Hollebecque et al. Cancer Discovery profile →
NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial

2023 185 citations Zev A. Wainberg, Davide Melisi et al. profile →

Peers

Countries citing papers authored by Davide Melisi

Since Specialization

Citations

This map shows the geographic impact of Davide Melisi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Davide Melisi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Davide Melisi more than expected).

Fields of papers citing papers by Davide Melisi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Davide Melisi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Davide Melisi. The network helps show where Davide Melisi may publish in the future.

Co-authorship network of co-authors of Davide Melisi

This figure shows the co-authorship network connecting the top 25 collaborators of Davide Melisi. A scholar is included among the top collaborators of Davide Melisi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Davide Melisi. Davide Melisi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Updated overall survival analysis with 29-month follow-up of NAPOLI 3. 2024 ·Journal of Clinical Oncology ·Maen Hussein, Gazala Khan, Sreenivasa R Chandana, Roberto Pazo-Cid, Igor Kišš, Javier Gállego, Teresa Macarulla, Christelle de la Fouchardière, Thorsten Oliver Goetze, Andrew Dean, Eileen M. O’Reilly, Zev A. Wainberg, Woo Jin Lee, Eric Van Cutsem, Richard Hubner, Andrew Scott Paulson, Tanios Bekaii‐Saab, Shubham Pant, Fiona Maxwell, Davide Melisi	2
2	Nrf2 Plays a Key Role in Erythropoiesis during Aging 2024 ·Antioxidants ·(unknown), Angela Siciliano, Alessandro Mattè, Enrica Federti, Massimiliano Perduca, Davide Melisi, Immacolata Andolfo, Angela Amoresano, Achille Iolascon, Maria Teresa Valenti, Francesco Turrini, (unknown), (unknown), Antonio Recchiuti, Domenico Mattoscio, (unknown), Luca Dalle Carbonare, Carlo Brugnara, Narla Mohandas, Lucia De Franceschi	6
3	Autotaxin Secretion Is a Stromal Mechanism of Adaptive Resistance to TGFβ Inhibition in Pancreatic Ductal Adenocarcinoma 2023 ·Cancer Research ·Silvia Pietrobono, (unknown), (unknown), (unknown), (unknown), Federica Fazzini, (unknown), (unknown), (unknown), Valeria Merz, Camilla Zecchetto, (unknown), Giusy Di Conza, Michael Lahn, Davide Melisi	15
4	Diagnosis and treatment of cholangiocarcinoma in Italy: A Delphi consensus statement 2023 ·Critical Reviews in Oncology/Hematology ·Lorenza Rimassa, Giovanni Brandi, Monica Niger, Nicola Normanno, Davide Melisi	5
5	p38 MAPK-dependent phosphorylation of transcription factor SOX2 promotes an adaptive response to BRAF inhibitors in melanoma cells 2022 ·Journal of Biological Chemistry ·Silvia Pietrobono, (unknown), (unknown), Andrea Marranci, Ilaria Battisti, Cinzia Franchin, Giorgio Arrigoni, Davide Melisi, Laura Poliseno, Barbara Stecca	4
6	Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer 2020 ·Clinical Cancer Research ·Valeria Merz, Camilla Zecchetto, Raffaela Santoro, Francesca Simionato, (unknown), (unknown), Geny Piro, Alessandro Cavaliere, Michela Deiana, Maria Teresa Valenti, (unknown), Vita Fedele, Sara Lonardi, Davide Melisi	19
7	Clinicogenomic Analysis of FGFR2 -Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib breakdown → 2020 ·Cancer Discovery ·Ian M. Silverman, Antoine Hollebecque, Luc Friboulet, Sherry Owens, Robert Newton, Hui‐Ling Zhen, Luis Féliz, Camilla Zecchetto, Davide Melisi, Timothy C. Burn	191
8	From Genetic Alterations to Tumor Microenvironment: The Ariadne’s String in Pancreatic Cancer 2020 ·Cells ·Chiara Bazzichetto, Fabiana Conciatori, Claudio Luchini, Francesca Simionato, Raffaela Santoro, Vanja Vaccaro, Vincenzo Corbo, Italia Falcone, G. Ferretti, Francesco Cognetti, Davide Melisi, Aldo Scarpa, Ludovica Ciuffreda, Michèle Milella	25
9	Angiopoietin-Like Proteins in Angiogenesis, Inflammation and Cancer 2018 ·International Journal of Molecular Sciences ·Carmine Carbone, Geny Piro, Valeria Merz, Francesca Simionato, Raffaela Santoro, Camilla Zecchetto, Giampaolo Tortora, Davide Melisi	161
10	Predictive biomarkers for the treatment of resectable esophageal and esophago-gastric junction adenocarcinoma: from hypothesis generation to clinical validation 2018 ·Expert Review of Molecular Diagnostics ·Geny Piro, Carmine Carbone, Raffaela Santoro, Giampaolo Tortora, Davide Melisi	4
11	Pancreatic Cancer and Obesity: Molecular Mechanisms of Cell Transformation and Chemoresistance 2018 ·International Journal of Molecular Sciences ·Priscilla Cascetta, Alessandro Cavaliere, Geny Piro, Lorena Torroni, Raffaela Santoro, Giampaolo Tortora, Davide Melisi, Carmine Carbone	40
12	Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients 2017 ·Clinical Cancer Research ·Carmine Carbone, Geny Piro, Francesca Simionato, Francesca Ligorio, Chiara Cremolini, Fotios Loupakis, Greta Alì, Daniele Rossini, Valeria Merz, Raffaela Santoro, Camilla Zecchetto, Marco Zanotto, Federica Di Nicolantonio, Alberto Bardelli, Gabriella Fontanini, Giampaolo Tortora, Davide Melisi	41
13	IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-κB Activation 2015 ·Clinical Cancer Research ·Zhuonan Zhuang, Huai‐Qiang Ju, Mitzi Aguilar, (unknown), Hao Li, Tomonori Iida, Harold Lee, (unknown), Haijun Zhou, Jianhua Ling, Zhongkui Li, Jie Fu, Min Wu, Min Li, Davide Melisi, Yoichiro Iwakura, Kesen Xu, Jason B. Fleming, Paul J. Chiao	95
14	Toll-Like Receptor 9 Agonists for Cancer Therapy 2014 ·Biomedicines ·Davide Melisi, Melissa Frizziero, Anna Tamburrino, Marco Zanotto, Carmine Carbone, Geny Piro, Giampaolo Tortora	32
15	Toll-like Receptor 9 Agonist IMO Cooperates with Cetuximab in K - Ras Mutant Colorectal and Pancreatic Cancers 2011 ·Clinical Cancer Research ·Roberta Rosa, Davide Melisi, Vincenzo Damiano, Roberto Bianco, Sonia Garofalo, Teresa Gelardi, Sudhir Agrawal, Federica Di Nicolantonio, Aldo Scarpa, Alberto Bardelli, Giampaolo Tortora	44
16	Anti-VEGF Treatment–Resistant Pancreatic Cancers Secrete Proinflammatory Factors That Contribute to Malignant Progression by Inducing an EMT Cell Phenotype 2011 ·Clinical Cancer Research ·Carmine Carbone, Tania Moccia, Cihui Zhu, (unknown), Alfredo Budillon, Paul J. Chiao, James L. Abbruzzese, Davide Melisi	80
17	Oral Poly(ADP-Ribose) Polymerase-1 Inhibitor BSI-401 Has Antitumor Activity and Synergizes with Oxaliplatin against Pancreatic Cancer, Preventing Acute Neurotoxicity 2009 ·Clinical Cancer Research ·Davide Melisi, Valeria Ossovskaya, Cihui Zhu, Roberta Rosa, Jianhua Ling, Patrick M. Dougherty, Barry M. Sherman, James L. Abbruzzese, Paul J. Chiao	32
18	Vascular Endothelial Growth Factor Receptor-1 Contributes to Resistance to Anti–Epidermal Growth Factor Receptor Drugs in Human Cancer Cells 2008 ·Clinical Cancer Research ·Roberto Bianco, Roberta Rosa, Vincenzo Damiano, Gennaro Daniele, Teresa Gelardi, Sonia Garofalo, Valeria Tarallo, Sandro De Falco, Davide Melisi, Roberto Benelli, Adriana Albini, Anderson J. Ryan, Fortunato Ciardiello, Giampaolo Tortora	117
19	LY2109761, a novel transforming growth factor β receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis 2008 ·Molecular Cancer Therapeutics ·Davide Melisi, Satoshi Ishiyama, Guido M. Sclabas, Jason B. Fleming, Qianghua Xia, Giampaolo Tortora, James L. Abbruzzese, Paul J. Chiao	262
20	Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect. 2003 ·PubMed ·Giampaolo Tortora, Rosa Caputo, Vincenzo Damiano, Davide Melisi, Roberto Bianco, Gabriella Fontanini, Bianca Maria Veneziani, Sabino De Placido, A R Bianco, Fortunato Ciardiello	134

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact